Krka, d. d. (LJSE:KRKG)

Market Cap	7.09B +36.7%
Revenue (ttm)	2.04B +6.9%
Net Income	403.24M +13.0%
EPS	13.21 +13.9%
Shares Out	30.31M
PE Ratio	17.71
Forward PE	17.85
Dividend	8.25 (3.53%)
Ex-Dividend Date	Jul 21, 2026

Volume	2,708
Average Volume	3,704
Open	234.00
Previous Close	n/a
Day's Range	233.00 - 235.00
52-Week Range	150.50 - 251.00
Beta	0.46
RSI	55.16
Earnings Date	Mar 12, 2026

About Krka, d. d.

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company’s prescription pharmaceuticals include medicines for the treatment of cardiovascular, gastrointestinal tract and metabolism, central nervous system, oncology, pain relief, antiinfectives for systemic use, antidiabetics, and other products. It provides non-prescription prod...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 13,236
• Stock Exchange: Ljubljana Stock Exchange
• Ticker Symbol: KRKG

Financial Performance

In 2025, Krka, d. d.'s revenue was 2.04 billion, an increase of 6.89% compared to the previous year's 1.91 billion. Earnings were 403.24 million, an increase of 12.96%.